News for Montes Archimedes Acquisition Corp. (MAACU)

Montes Archimedes Acquisition (ROIV) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

The average of price targets set by Wall Street analysts indicates a potential upside of 35.1% in Montes Archimedes Acquisition (ROIV). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.

Roivant Sciences Ltd., with its differentiated drug development pipeline and strategic investments, shows strong upside prospects in 2024. Click for my ROIV update.

Roivant Sciences recently won approval for a topical cream, VTAMA, that looks set to achieve blockbuster sales. Learn why I rate ROIV stock as a buy.

Ramaswamy, who has declared that he is running for president as a Republican, has accumulated a significant fortune thanks to a biotech firm he launched nine years ago and his fledgling ‘anti-woke’ investment firm.

Today we look at two Republicans who have announced they are running for president, as well as a third who is expected to do likewise.

The anti-woke crusader and entrepreneur is padding his pockets with cash as his presidential campaign gets going.

Roivant has drugs targeting multi-billion dollar autoimmune markets, with one already approved. Read more on why Roivant stock could see upside.

Read Roivant Sciences Ltd (NASDAQ:ROIV) CAO Rakhi Kumar Sells 7,281 Shares of Stock at ETF Daily News

Read Roivant Sciences (NASDAQ:ROIV) Hits New 12-Month Low at $4.75 at ETF Daily News

GuruFocus Article or News written by insider and the topic is about:

The month of September marks a slow down in deal votes after recent months but still offers up several well-known companies that will go publ...

GuruFocus Article or News written by insider and the topic is about: